Director
Eli Lilly and Company
Indianapolis, Indiana
Stephen D. Stamatis, Ph.D. is a Director in Synthetic Molecule Design & Development at Eli Lilly and Company. He completed his B.S.E. in Chemical Engineering at the University of Michigan and Ph.D. in Chemical Engineering from Purdue University. His thesis work focused on Bayesian approaches to parameter uncertainty assessment in microkinetic models of catalysis. Dr. Stamatis completed a postdoctoral fellowship at the University of Iowa in pharmaceutics where he developed whole body physiologically based pharmacokinetic models to asses drug product stability risk. He joined Eli Lilly and Company in 2013 developing oral absorption models for several assets. His current work focuses on the application and development of biopharmaceutics models in drug discovery through late phase commercialization with an emphasis on drug product performance.
Disclosure information not submitted.
Linking In-vivo Predictive Dissolution Data with Pre-clinical and Clinical Studies
Tuesday, October 22, 2024
10:30 AM – 11:00 AM MT
Hot Topic: Trends in Utility of Animal Studies in Oral Drug Development
Wednesday, October 23, 2024
3:00 PM – 4:00 PM MT